A new option for millions looking to try those popular weight loss drugs without having to use a needle. The FDA approving Eli Liy's new GLP1 pill called FO set to hit the market next week. Feoo's selling point takes convenience one step further.Unlike WGOi, you don't have to take FO on an empty stomach and then wait 30 minutes to eat or drink. While not as effective as the injections, both pills help people lose weight. Studies show patients who took the highest dose of Fondo lost 12% of their body weight ...

The race to offer cheaper weight loss drugs is running into some legal limits. Tellahalth company Hims and Hers announced a cheaper version of Novo's Waggoi weight loss pill at the beginning of February. Now, it would cost $49 to start, which is far less than the $149 Novo sells the branded pill for, but it pulled the drug after legal and regulatory risks escalated.Now, legally, they're allowed to create a compounded version of a drug if they are saying they're adjusting the formula for quote personalized p ...

The race to offer cheaper weight loss drugs is running into some legal limits. Telehealth company Hims & Hers announced a cheaper version of Novo's Wegovy weight-loss pill at the beginning of February. Now it would cost $49 to start, which is far less than the $149 Novo sells the branded pill for.But it pulled the drug after legal and regulatory risks escalated. Now, legally, they're allowed to create a compounded version of a drug if they are saying they're adjusting the formula for "personalized purposes. ...

Core Insights - Eli Lilly's stock experienced a significant increase of 39% over the past year, driven by the success of its weight loss drugs [1] - The obesity drug market is projected to reach nearly $100 billion by the end of the decade, indicating strong growth potential [2] Company Overview - Viking Therapeutics specializes in treatments for metabolic and endocrine disorders and is currently developing weight loss candidates in late-stage clinical trials [4] - The company's VK2735, available in both injectable and oral forms, functions similarly to Lilly's tirzepatide, targeting hormones that regulate blood sugar and appetite [5] Clinical Development - Viking's VK2735 has shown promising results in clinical trials, with a reported weight loss of up to 14.7% in a phase 2 trial after 13 weeks [5] - The drug is currently in phase 3 and phase 2 trials, indicating progress towards potential market entry [4] Market Competition - VK2735 has the potential to compete with established products like Lilly's tirzepatide and Novo Nordisk's semaglutide, although direct comparisons are challenging due to differing trial parameters [7] - Despite the dominance of major pharmaceutical companies, there is a consistent demand for weight loss drugs, suggesting opportunities for new entrants like Viking [8] Investment Potential - If successful, Viking Therapeutics could see substantial rewards due to the high demand for weight loss drugs and the potential for partnerships or acquisitions by larger companies [9] - The stock is considered a top biotech investment for 2026, appealing to investors willing to accept the risks associated with drug development [9]

Health & Policy - The discussion revolves around President Trump's executive order to reinstate the presidential fitness test in public schools, initially established in 1956 by President Eisenhower [1] - The policy is viewed as performative and political theater, unlikely to address childhood obesity effectively [4] - The core issue lies in structural problems such as limited access to healthy food, a flawed healthcare system, unsafe neighborhoods for exercise, and insufficient recess or physical education [5][6] - Michelle Obama's "Let's Move" campaign, aimed at promoting physical activity and healthy school lunches, faced ridicule from conservatives, highlighting potential political motivations behind health initiatives [10][11] Obesity & Treatment - Over 70% of children and 85% of teenagers do not meet the 2024 federal minimum recommendation for daily moderate to vigorous physical activity, with higher rates among children of color [3] - The administration plans to experiment with Medicare and Medicaid coverage for weight loss drugs like Ozempic and Wegovy, addressing disparities in obesity treatment access [13] - While medication is beneficial, it's not a complete solution; preventive and wraparound services are essential, raising concerns about Medicaid cuts affecting state affordability of GLP-1s [14][15] Nutrition & Systemic Issues - The administration's focus on changing ingredients in junk food is seen as addressing issues on a granular level rather than tackling systemic problems [17][18] - Addressing the underinsured and uninsured populations, predominantly people of color, is crucial for ensuring access to preventive care and resolving systemic issues impacting communities [19]

Company Transformation - Novo Nordisk's weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant [1] Market Value - Four years after Wegovy's US launch, the Danish drugmaker's market value has plummeted [1]